Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Thy-1 or CD90 (Cluster of Differentiation 90) is a 25–37 kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored conserved cell surface protein with a single V-like immunoglobulin domain, originally discovered as a thymocyte antigen. Thy-1 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Structural study of Thy-1 led to the foundation of the Immunoglobulin superfamily, of which it is the smallest member, and led to some of the initial biochemical description and characterization of a vertebrate GPI anchor and also the first demonstration of tissue specific differential glycosylation.
Subsequent clinical research has found that monotherapy with higher dosages of NSAAs than those used in CAB is roughly equivalent to castration in extending life in men with prostate cancer. Moreover, NSAA monotherapy is overall better tolerated and associated with greater quality of life than is castration, which is thought to be related to the fact that testosterone levels do not decrease with NSAA monotherapy and hence by extension that levels of biologically active and beneficial metabolites of testosterone such as estrogens and neurosteroids are preserved. For these reasons, NSAA monotherapy has become an important alternative to castration and CAB in the treatment of prostate cancer. Bicalutamide may be used to reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy. The combination of bicalutamide with an estrogen such as ethinylestradiol sulfonate has been used as a form of CAB and as an alternative to the combination of bicalutamide with surgical or medical castration.
Pyruvate dehydrogenase complex (PDC) is a complex of three enzymes that converts pyruvate into acetyl-CoA by a process called pyruvate decarboxylation. Acetyl-CoA may then be used in the citric acid cycle to carry out cellular respiration, and this complex links the glycolysis metabolic pathway to the citric acid cycle. Pyruvate decarboxylation is also known as the "pyruvate dehydrogenase reaction" because it also involves the oxidation of pyruvate. The levels of pyruvate dehydrogenase enzymes play a major role in regulating the rate of carbohydrate metabolism and are strongly stimulated by the evolutionarily ancient hormone insulin. The PDC is opposed by the activity of pyruvate dehydrogenase kinase, and this mechanism plays a pivotal role in regulating rates of carbohydrate and lipid metabolism in many physiological states across taxa, including feeding, starvation, diabetes mellitus, hyperthyroidism, and hibernation. The multienzyme complex is structurally and functionally related to the oxoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (OADHC) and the branched-chain oxo-acid dehydrogenase complex (BCKDC), all of which are members of the 2-oxoacid dehydrogenase complex family. A role for insulin in the regulation of glucose homeostasis, pyruvate dehydrogenase levels, and the generation of AMP-activated protein kinase (AMPK) in the electron transport chain has been evolutionarily conserved across species.
One common issue faced by many cell lysis buffers is the disruption of protein structures during the lysis process, partially caused by use of detergents. Detergents often prevent the restoration of native conditions necessary for proper protein folding. For the longest time, after a detergent-based cell lysis, a buffer exchange and/or dialysis had to be performed to remove the detergent among other hindering compounds to restore native conditions. To overcome this a solution has emerged in the form of a detergent-free cell lysis buffer. The GentleLys buffer employs copolymers instead of detergents, ensuring efficient cell lysis while maintaining the native environment crucial for the correct folding of cellular components, such as proteins.
Sources: en.wikipedia.org
Having witnessed the crucial role of space to United States military success in the Gulf War, China continues to view space as a critical domain in both conflict and international strategic competition. The PLA operates a various satellite constellations performing reconnaissance, navigation, communication, and counterspace functions. Planners at PLA's National Defense University project China's space actions as retaliatory or preventative, following conditions like an attack on a Chinese satellite, an attack on China, or the interruption of a PLA amphibious landing. According to this approach, PLA planners assume that the country must have the capacity for retaliation and second-strike capability against a powerful opponent. PLA planners envision a limited space war and therefore seek to identify weak but critical nodes in other space systems. Significant components of the PLA's space-based reconnaissance include Jianbing (vanguard) satellites with cover names Yaogan (遥感; 'remote sensing') and Gaofen (高分; 'high resolution'). These satellites collect electro-optical (EO) imagery to collect a literal representation of a target, synthetic aperture radar (SAR) imagery to penetrate the cloudy climates of southern China, and electronic intelligence (ELINT) to provide targeting intelligence on adversarial ships. The PLA also leverages a restricted, high-performance service of the country's BeiDou positioning, navigation, and timing (PNT) satellites for its forces and intelligence, surveillance, and reconnaissance (ISR) platforms.
the exact colour of the spore powder (white/cream/ochre), the taste (mild/bitter/acrid), colour changes in the flesh, the distance from the centre to which the cap skin can be pulled off: (peeling percentage). cap colour (but this is often very variable within one species), reaction of the flesh to ferrous sulphate (FeSO4), formalin, alkalis, and other chemicals, ornamentation of the spores, and other microscopic characteristics, such as the appearance of the cystidia in various mounting reagents. Despite the difficulty in positively identifying collected specimens, the possibility to spot the toxic species by their acrid taste makes some of the mild species, such as R. cyanoxantha and R. vesca, popular edible mushrooms. Russula is mostly free of deadly poisonous species, and mild-tasting ones are all edible.
β2 microglobulin provides stability of the complex and participates in the recognition of peptide-MHC class I complex by CD8 co-receptor. The peptide is non-covalently bound to MHC-I, it is held by the several pockets on the floor of the peptide-binding groove. Amino acid side-chains that are most polymorphic in human alleles fill the central and widest portion of the binding groove, while conserved side-chains are clustered at the narrower ends of the groove.
=== Adenovirus and cytomegalovirus === As of 2014, brincidofovir is in Phase III clinical trials for use in humans against cytomegalovirus and adenovirus. Preliminary safety data from a database of 1000 patients supported progression into later phase trials, Chimerix announced in December 2015 that the Phase III trials for use of the drug in preventing cytomegalovirus infection in stem cell transplant patients had failed, and in February 2016 shut down two other late-stage trials for use of the drug in preventing infection after kidney transplants. Brincidofovir is not yet FDA approved for adenovirus or cytomegalovirus due to lack of efficacy in clinical trials. In a trial of brincidofovir for CMV prophylaxis in stem cell transplant patients, brincidofovir was associated with a 15.5% week 24 all-cause mortality compared with 10.1% among placebo recipients. Additionally brincidofovir was associated with increased serious adverse events (57.1% versus 37.6%) compared with placebo. Brincidofovir was initially offered via an FDA expanded access trial; however as of 9 May 2019, Chimerix discontinued clinical trials of brincidofovir for the treatment of adenovirus and discontinued the expanded access program in 2019.
== History and development == Researchers at the University of Nebraska Medical Center and Longevity Biotech, Inc. in Philadelphia first demonstrated the use of the drug in mouse models. A phase I trial for humans was planned for 2017, but as of 2018 it was still in the preclinical development stage.
Sources: en.wikipedia.org
hypotonic Describing a solution containing a low concentration of dissolved solutes relative to another solution, i.e. having negative osmotic pressure, such that solvent will tend to move by osmosis across a semipermeable membrane from the solution of lower solute concentration to the solution of higher concentration until both solutions have equal concentrations. In a cell where the intracellular cytosol is hypotonic relative to the surrounding extracellular fluid (which by definition is hypertonic relative to the cytosol), the solvent (water) will flow across the plasma membrane out of the cytosol, causing the cell to lose water until both sides of the membrane are isotonic. Cells placed in severely hypertonic environments may be at risk of shriveling and desiccating due to the sudden outflow.
It is a measurement of the contribution of a genotype to the next generation where a value of 1 would be completely selected against and make no contribution and 0 is not selected against at all. This definition of neutral mutation has been criticized due to the fact that very large effective population sizes can make mutations with small selection coefficients appear non neutral. Additionally, mutations with high selection coefficients can appear neutral in very small populations. The testable hypothesis of Kimura and others showed that polymorphism within species are approximately that which would be expected in a neutral evolutionary model. For many molecular biology approaches, as opposed to mathematical genetics, neutral mutations are generally assumed to be those mutations that cause no appreciable effect on gene function. This simplification eliminates the effect of minor allelic differences in fitness and avoids problems when a selection has only a minor effect. Early convincing evidence of this definition of neutral mutation was shown through the lower mutational rates in functionally important parts of genes such as cytochrome c versus less important parts and the functionally interchangeable nature of mammalian cytochrome c in in-vitro studies. Nonfunctional pseudogenes provide more evidence for the role of neutral mutations in evolution. The rates of mutation in mammalian globin pseudogenes has been shown to be much higher than rates in functional genes.
Potassium is a soft silvery solid that is easily cut with a knife. Because of the sensitivity of potassium to water and air, air-free techniques are normally employed for handling the element. It is unreactive toward nitrogen and saturated hydrocarbons such as mineral oil or kerosene. It readily dissolves in liquid ammonia, up to 480 g per 1000 g of ammonia at 0 °C to form the electride [K(NH3)6]+e−, which features an electron as an anion.
The main gas supply for surface-supplied diving can be from high pressure bulk storage cylinders. When the storage cylinders are relatively portable this is known as a scuba replacement system in the commercial diving industry. The application is versatile and can ensure high quality breathing gas in places where atmospheric air is too contaminated to use through a normal low pressure compressor filter system, and is easily adaptable to a mixed gas supply and oxygen decompression provided that the breathing apparatus and gas supply system are compatible with the mixtures to be used. Scuba replacement is often used from smaller diving support vessels, for emergency work, and for hazmat diving. Mixed breathing gases are provided from high pressure bulk storage systems for saturation diving, but these are less portable, and generally involve manifolded racks of cylinders of approximately 50 litres water capacity arranged as quads and even larger racks of high pressure tubes. If gas reclaim systems are used, the reclaimed gas is scrubbed of carbon dioxide, filtered of other contaminants, and recompressed into high pressure cylinders for interim storage, ans is generally blended with oxygen or helium to make up the required mix for the next dive before re-use.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.